Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fidelity MSCI Health Care Index ETF (FHLC) charges a lower 0.08% expense ratio vs iShares U.S. Pharmaceuticals ETF (IHE) at 0.37% (29 bps cheaper) and holds 338 stocks vs 56, reducing concentration risk. However, IHE has outperformed over the past year with a 60% total return (vs FHLC’s 33.7%) as of Aug. 10, 2026, while dividend yields are similar (1.4% IHE vs 1.3% FHLC). The article concludes FHLC is the better buy due to diversification and lower fees despite weaker recent returns.

Analysis

This is mostly a flow and vehicle-selection story, not a fundamental healthcare catalyst. The marginal buyer who wants sector exposure but not single-name risk is more likely to migrate into the lower-fee, broader vehicle, which should support the large-cap healthcare complex while leaving the more concentrated pharma basket dependent on a handful of headline-sensitive names. In practice, that means the sector’s beta is probably better owned through a diversified wrapper unless you have a specific view on drug pricing, GLP-1 share gains, or litigation outcomes.

The key second-order effect is concentration risk: a narrow pharma sleeve can outperform sharply when one or two leaders rerate, but it also transmits single-name disappointment directly into the fund. That makes the relative trade more about event dispersion than about healthcare beta. Over the next 1-3 months, earnings and guidance from LLY, JNJ, ABBV, and BMY are the real catalyst set; over 6-18 months, fee sensitivity and structural allocation preferences should keep favoring the cheaper, broader exposure as the default core holding.

The contrarian angle is that the recent outperformance of the concentrated pharma basket may already be doing the work of a bullish single-name call, so buying the ETF here is just a crowded way to express what is really an LLY/JNJ opinion. If those leaders disappoint, the ETF’s diversification will not save investors much because the top weights dominate returns. The move would be falsified if a new drug or regulatory catalyst lifts one of the top holdings enough to overwhelm fee drag and diversify-away arguments.

Key Decisions for Investors

• Use FHLC as the default healthcare beta for the next 1-3 months; it is the cleaner core allocator if the goal is reduced single-name risk and lower fee drag.
• Avoid adding new IHE exposure at current levels unless you have a separate bullish view on LLY/JNJ/ABBV; the ETF is effectively a concentrated top-holdings bet, not broad pharma diversification.
• Relative-value idea: long FHLC / short IHE on a 1-3 month horizon if the market shifts toward lower-volatility healthcare exposure. Keep sizing modest because the spread is still dominated by a few mega-cap catalysts.
• If you want to express bullish pharma innovation, prefer direct longs in LLY or ABBV over IHE; the ETF structure dilutes upside while still leaving you exposed to concentration drawdowns.